Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs

NCT04811443 is registered in ClinicalTrials.gov with Biocad as lead sponsor.

NCT NCT04811443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04811443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs
Lead sponsor
Biocad
Phase
Observational
Overall status
Unknown status
Start date
January 12, 2021
Completion date
June 12, 2022
Enrollment
500 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

patients with solid tumours who receive myelosupressive therapy